目的:探讨牛磺酸上调基因1（taurine upregulated gene 1, TUG1）在弥漫性大B 细胞淋巴瘤（diffuse large B-cell Lymphoma，DLBCL）患者组织标本中的表达，分析TUG1 表达与DLBCL患者临床特征及其预后的关系。方法：收集108 例2011 年1 月至2016 年12 月在西南医科大学附属第一医院血液科确诊为DLBCL 的初诊患者和同期47 例反应性淋巴结增生（reactive lymphoid hyperplasia，RLH）患者的组织标本，通过qPCR方法检测DLBCL和RLH患者组织标本中TUG1 的表达，采用Chi-Square 检验、Kaplan-Meier 法和单因素及多因素分析法分别分析TUG1 mRNA表达水平与DLBCL患者临床病理特征的关系和影响DLBCL患者生存时间及预后的因素。结果：TUG1 mRNA在DLBCL患者组织中的表达显著高于RLH患者（6.108±0.332 vs 1.231±0.095，P<0.01），TUG1 mRNA表达与DLBCL患者的疾病分期、肿瘤大小、B细胞症状、IPI 指数、GCB亚型及化疗敏感性显著相关（均P<0.01），TUG1 表达量、疾病分期及肿瘤大小是影响DLBCL患者总生存时间（overall survival, OS）的因素。TUG1 mRNA表达、疾病分期、IPI 指数和化疗敏感性是影响DLBCL患者预后的因素。结论：TUG1 mRNA在DLBCL组织中高表达，是影响患者预后的独立因素，TUG1有可能成为DLBCL患者新的预后评估标志物和基因治疗DLBCL的潜在靶点。

Objective: To explore expression of taurine upregulated gene 1 (TUG1) in tissue specimens of the patients with diffuse large B-cell lymphoma (DLBCL) and to analyze correlation between expression of TUG1 and clinical features as well as prognosis of the patients with DLBCL. Methods: Tissue specimens of 108 patients who were diagnosed as DLBCL in Department of Hematology, the 1st Hospital affiliated to Southwestern Medical University during January 2011 to December 2016 and 47 patients with reactive lymphoid hyperplasia (RLH) during the same period were collected. qPCR assay was used to detect expressions of TUG1 mRNA in the tissue specimens of the patients with DLBCL or RLH. The relationship between expression level of TUG1 mRNA and clinical pathological features of the patients with DLBCL as well as factors affecting survival time and prognosis of the patients with DLBCL were analyzed by Chi-Square test, Kaplan-Meier assay, univariate and multivariate assays respectively. Results:Expression of TUG1 mRNA in the patients with DLBCL was obviously higher than that in the patients with RLH (6.108±0.332 vs 1.231±0.095, P<0.01). Expression of TUG1 mRNA was evidently related to disease staging,tumor size, B cell symptom, IPI index, GCB subtype and chemotherapy sensitivity in the patients with DLBCL (all P<0.01). Expression of TUG1 mRNA, disease staging and tumor size were the factors affecting over survival time (OS) of the patients with DLBCL (all P<0.05). Expression of TUG1 mRNA, disease staging, IPI index and chemotherapy sensitivity were the factors effecting on prognosis of the patients with DLBCL. Conclusion: TUG1 mRNA was highly expressed in the DLBCL tissues and was the independent factor effecting on prognosis of the patients with DLBCL. TUG1 might be as a novel marker which evaluates prognosis of the patients with DLBCL and as a po-tential target point for gene therapy of DLBCL.